Prescription medicine
Elotuzumab Brand names: Empliciti
Elotuzumab (Empliciti) is a prescription medicine with an FDA approval on record since 2015. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the elotuzumab FDA label on DailyMed (effective March 22, 2022, E.R. Squibb & Sons, L.L.C.); the BLA 761035 record on Drugs@FDA; every elotuzumab label on DailyMed.
Highlights of the record
FDA label of March 22, 2022; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageEMPLICITI is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies.
Forms and strengths
- 300 mg
- 400 mg
Injection (powder) (lyophilized) for solution.
On the market
- Earliest approval on file
- November 30, 2015 Empliciti, Bristol Myers Squibb; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 5,137 through July 30, 2026
What is elotuzumab used for?
From the label: indications and usageEMPLICITI is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies.
EMPLICITI is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. EMPLICITI is a SLAMF7-directed immunostimulatory antibody indicated in
combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies. […]
Conditions named in the indications of elotuzumab's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: SLAMF7-directed Immunostimulatory Antibody.
Source: FDA drug label (EMPLICITI), E.R. Squibb & Sons, L.L.C., effective March 22, 2022 (SPL set 80686b7e-f6f4-4154-b5c0-c846425e2d91), via openFDA; the full label on DailyMed
Is there a generic for elotuzumab (Empliciti)?
No generic elotuzumab is approved (Drugs@FDA, October 8, 2026).
- 2015 earliest approval on file
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the elotuzumab label say about other medicines?
The elotuzumab label names 4 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Acetaminophen | warnings and precautions | Administer premedication consisting of dexamethasone, antihistamines (H1 and H2 blockers) and acetaminophen prior to EMPLICITI infusion [see Dosage and Administration (2.3) ]. |
| Dexamethasone | drug interactions | DRUG INTERACTIONS 7.1 Drug Interactions For important drug interactions involving lenalidomide, pomalidomide and dexamethasone, refer to their respective prescribing information. |
| Lenalidomide | drug interactions | DRUG INTERACTIONS 7.1 Drug Interactions For important drug interactions involving lenalidomide, pomalidomide and dexamethasone, refer to their respective prescribing information. |
| Pomalidomide | drug interactions | DRUG INTERACTIONS 7.1 Drug Interactions For important drug interactions involving lenalidomide, pomalidomide and dexamethasone, refer to their respective prescribing information. |
Source: FDA drug label (EMPLICITI), E.R. Squibb & Sons, L.L.C., effective March 22, 2022 (SPL set 80686b7e-f6f4-4154-b5c0-c846425e2d91), via openFDA; the full label on DailyMed
What do FAERS reports show for elotuzumab?
The FDA Adverse Event Reporting System holds 5,137 reports that list elotuzumab among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 918 are coded as a death and 2,010 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as elotuzumab?
36 other medicines are given the same way (intravenous) and in the same FDA class as elotuzumab or labeled mainly for the same use (leukemia, lymphoma and myeloma), the same class first. Leukemia, lymphoma and myeloma lists all 98 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (intravenous) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Cyclophosphamide | Leukemia, lymphoma and myeloma | 15 labelers | n/a | No current entry |
| Doxorubicin | Leukemia, lymphoma and myeloma | 16 labelers | n/a | No current entry |
| Bortezomib | Leukemia, lymphoma and myeloma | 22 labelers | n/a | No current entry |
| Arsenic trioxide | Leukemia, lymphoma and myeloma | 16 labelers | n/a | A presentation being discontinued |
| Bendamustine | Leukemia, lymphoma and myeloma | 4 labelers | n/a | A presentation being discontinued |
| Nelarabine | Leukemia, lymphoma and myeloma | 12 labelers | n/a | No current entry |
| Idarubicin | Leukemia, lymphoma and myeloma | 2 labelers | n/a | No current entry |
| Clofarabine | Leukemia, lymphoma and myeloma | 9 labelers | n/a | No current entry |
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Elotuzumab side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other